Sanofi Invests €300M in Belgium Site to Expand Monoclonal Antibodies Portfolio
Investment Overview
Sanofi has announced a €300 million investment to expand its site in Geel, Belgium. This investment aims to enhance Sanofi’s manufacturing and commercial capabilities, ensuring quality, capacity, and scale for its biologics portfolio.
Facility Expansion
The investment will adapt and expand existing production capabilities to support Sanofi’s pipeline of monoclonal antibodies. The updates will include new laboratories focused on quality control and manufacturing sciences. The facility will add more than 8000 m² of manufacturing floor space, increasing overall production capacity and diversifying to other drugs and therapeutic areas.
Support and Collaboration
Sanofi has received support from the Government of Flanders, the Flanders Investment and Trade, and the Flanders Entrepreneurship agency. This collaboration underscores the region's commitment to fostering international trade and investments in the life sciences sector.
Current Operations
The Geel site, which began industrial biotech activities in 2001, has already seen €600 million in investments. It is responsible for the global production of a protein therapy for Pompe disease, a rare genetic muscular disease. The therapy is produced using cell cultures in large bioreactors, followed by a purification process.
Future Plans
As part of its strategic roadmap, Sanofi aims to launch several biologics in the upcoming years. The company plans to recruit highly-skilled biotechnology professionals to support the expanded operations and deliver high-quality products that could improve patient outcomes.
